About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Stanford University Secures NIH Grant to Advance tiakis Biotech´s Elafin (Tiprelestat) Through a U.S. Phase II Trial in Pulmonary Arterial Hypertension

- Novel, disease-modifying treatment option for Pulmonary Arterial Hypertension (PAH), an orphan indication with a significant unmet medical need

Kiel, GERMANY, September 8, 2025 – tiakis Biotech AG (“tiakis”), a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced that its long-standing collaboration partner Stanford University has been awarded a US$ double-digit million grant from the National Institutes of Health (NIH) - National Heart Lung and Blood Institute (NHLBI) - the Lung Division, to fund a U.S. Phase II trial of Tiprelestat for the treatment of Pulmonary Arterial Hypertension (PAH). In early 2025, the U.S. FDA has issued positive scientific advice on the planned trial design. The first patients are expected to be treated by Stanford University in mid-2026.

Tiprelestat has been developed by tiakis as an investigational disease-modifying therapy for PAH that has the ability to address the underlying inflammation and potentially reverse the vascular remodeling caused by this debilitating and fatal rare disease. Tiprelestat has already demonstrated an excellent safety profile in five clinical trials involving over 100 subjects. Tiprelestat has received orphan designation for PAH in the U.S. and in Europe. tiakis will provide Stanford with the clinical trial materials for this U.S. study at its own expense.

Existing PAH treatments aim to restore the balance of vasoconstriction and vasodilation, targeting pathways such as endothelin, nitric oxide, and prostacyclin. Nevertheless, the 5-year survival rate in PAH is only 57%, according to registry data. Therefore, there is an urgent medical need for new therapies specifically targeting pulmonary vascular remodeling and inflammation.

“The NIH grant is an outstanding validation and recognition of Tiprelestat’s robust science and its potential to deliver a truly transformative therapy for PAH patients. The investigative team thanks tiakis, our long-standing collaboration partner, for its commitment to supporting Stanford University in this U.S. Phase II trial,” said Professor Roham Zamanian, MD, Director of the Adult Pulmonary Hypertension Program at Stanford University and Principal Investigator of the trial.

“Tiprelestat holds the promise of a disease-modifying therapy because of its unique mechanism of action which addresses major pathological processes in PAH, specifically inflammation and BMPR2 deficiency,“ added Professor Marlene Rabinovitch, MD, the Dwight and Vera Dunlevie Professor of Pediatric Cardiology, and Director of the Basic Science and Engineering Initiative of the Children's Heart Center at Stanford University and Principal Investigator of the trial. “Data from the planned U.S. Phase II trial are expected to confirm this hypothesis.”

“We would like to congratulate Drs. Roham Zamanian and Marlene Rabinovitch on receiving this prestigious NIH award. We also congratulate the leader of the companion award to the Data Coordinating Center for this trial, Dr. Cathie Spino at the SABER unit of the University of Michigan. This award recognizes Tiprelestat’s potential and pioneering approach by scientific and clinical experts at this well-respected institute,” said Martin Voss, CEO of tiakis Biotech AG.

Research reported in this publication will be supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number UG3HL180990. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

About tiakis Biotech

tiakis Biotech AG is an innovative, clinical-stage pharmaceutical company specializing in groundbreaking approaches to protect human tissues and organ structures. The Company develops anti-inflammatory treatments with a primary focus on pulmonary arterial hypertension (PAH). tiakis´ lead candidate Tiprelestat is in clinical development and addresses unmet medical needs in life-threatening conditions. The Company is based in Kiel, Germany.

For further information, please visit https://tiakis.bio.

Contact

tiakis BIOTECH AG
Sophienblatt 40
24103 Kiel
Germany
phone: +49 431 8888-462
fax: +49 431 8888-463
email: info@tiakis.bio

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 / +49 30 23 63 27 68

Stanford University
Roham T. Zamanian, MD, FCCP
Professor of Medicine
Director, Adult Pulmonary Hypertension Program
Associate Director, Vera Moulton Wall Center for Pulmonary Vascular Disease
Division of Pulmonary & Critical Care Medicine
Stanford University School of Medicine
email: zamanian@stanford.edu


More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.22
+1.41 (0.78%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.